Spatial distribution of introduced brook trout Salvelinus fontinalis (Salmonidae) within alpine lakes: evidences from a fish eradication campaign

Brook trout Salvelinus fontinalis have been used worldwide to stock fishless alpine lakes, negatively affecting native biota. Understanding its spatial ecology in invaded ecosystems can provide information to interpret and contrast its ecological impact. We opportunistically used capture points of brook trout gillnetted during an eradication campaign to assess the distribution patterns of four unexploited populations inhabiting high-altitude lakes. The main eradication method implies the use of many gillnets with several mesh sizes, which are selective for different fish sizes. For each lake we drew six capture maps associated with as many different mesh sizes, and we tested whether the distance from the coastline (which in alpine lakes is a reliable proxy of the most important spatial gradients, e.g. depth, temperature, prey availability, lighting conditions) influences the proportion of captured fish belonging to different size classes and the number of fish captured by the nets with different mesh sizes. To interpret the results, we also provide a cartographic description of the lakes’ bathymetry and littoral microhabitats. We found (1) a negative relationship between brook trout distribution and the distance from the coastline in all of the size classes, lakes and mesh sizes; (2) that large brook trout can thrive in the lakes’ center, while small ones are limited to the littoral areas; and (3) that the distance from the coastline alone cannot explain all the differences in the catch densities in different parts of the lakes. As in their native range, introduced brook trout populations also have littoral habits. Microhabitats, prey availability and distance from the spawning ground are other likely factors determining the distribution patterns of brook trout populations introduced in alpine lakes. The obtained results also provide useful information on how to plan new eradication campaigns

Itraconazole as 'bridge therapy' to anti-IgE in a patient with severe asthma with fungal sensitisation.

Sensitisation to fungi has been reported to play an important role in a particular phenotype of severe asthma, the so-called severe asthma with fungal sensitisation, characterised by high levels of total IgE, which may be an obstacle to anti-IgE therapy. We describe here the case of a polysensitised woman with refractory asthma, sensitised to Aspergillus fumigatus with high total IgE values (1793 kUA/l), but without the diagnostic criteria for allergic bronchopulmonary aspergillosis. Additional therapy with itraconazole leads to the decrease of total IgE to the limits recommended for proper omalizumab dosing (30–1500 kUA/l). Itraconazole, used as bridge therapy, provided us the opportunity to start anti-IgE treatment in a patient with high levels of total IgE, beyond the upper limits recommended for proper prescription of omalizumab

History of Archeological Investigations at Palo Duro Canyon State Park

Palo Duro Canyon has been an important locale for human occupation with its distinct topography, fauna, and flora from the Paleoindian inhabitants to those of the Historic Period. There is archeological evidence of human habitation at Palo Duro Canyon throughout the past 12 millennia. Native Americans who lived in and around the canyon had access to resources not easily found on the adjoining upland plains. The canyon provided an abundance of sheltered camping and year-round supply to water, wood, stone tool materials, game, and wild plant resources. The bordering uplands, covered with grass and dotted with playa lakes, afforded campsites with good visibility and access to game such as bison, antelope, and waterfowl. This article reviews the history of archaeological work conducted at Palo Duro Canyon State Park since the park opened in 1934. It examines how evolving site recording standards, archaeological methods, and construction projects have influenced the types of archaeological investigations that have been conducted within the park over time. These investigations have occurred within the context of larger changes to the discipline and, more recently, expansions to the original park boundaries. Together, they help elucidate on the rich history of human occupation in the region

Host genetics and gut microbiome: Perspectives for multiple sclerosis

As a complex disease, Multiple Sclerosis (MS)’s etiology is determined by both genetic and environmental factors. In the last decade, the gut microbiome has emerged as an important environmental factor, but its interaction with host genetics is still unknown. In this review, we focus on these dual aspects of MS pathogenesis: we describe the current knowledge on genetic factors related to MS, based on genome-wide association studies, and then illustrate the interactions between the immune system, gut microbiome and central nervous system in MS, summarizing the evidence available from Experimental Autoimmune Encephalomyelitis mouse models and studies in patients. Finally, as the understanding of influence of host genetics on the gut microbiome composition in MS is in its infancy, we explore this issue based on the evidence currently available from other autoimmune diseases that share with MS the interplay of genetic with environmental factors (Inflammatory Bowel Disease, Rheumatoid Arthritis and Systemic Lupus Erythematosus), and discuss avenues for future research

Eosinophils Target Therapy for Severe Asthma: Critical Points

Asthma is a chronic and heterogeneous disease, which is defined as severe disease whenever it requires treatment with a high dose of inhaled corticosteroids plus a second controller and/or systemic corticosteroids to prevent it from becoming ‘‘uncontrolled’’ or if it remains ‘‘uncontrolled’’ despite this therapy. Severe asthma is a heterogeneous condition consisting of phenotypes such as eosinophilic asthma, which is characterized by sputum eosinophilia, associated with mild to moderate increase in blood eosinophil count, frequently adult-onset, and associated with chronic rhinosinusitis with nasal polyps in half of the cases. Eosinophilic asthma is driven by T2 inflammation, characterized, among the others, by interleukin-5 production. IL-5 plays a key role in the differentiation, survival, migration, and activation of eosinophils, and it has become an appealing therapeutic target for eosinophilic asthma. In recent years two monoclonal antibodies (mepolizumab and reslizumab) directed against IL-5 and one monoclonal antibody directed against the alpha-subunit of the IL-5 receptor (benralizumab) have been developed. All these IL-5 target drugs have been shown to reduce the number of exacerbation in patients with severe asthma selected on the basis of peripheral blood eosinophil count. There are still a number of unresolved issues related to the anti-IL5 strategy in eosinophilic asthma, which are here reviewed. These issues include the effects of such therapy on airway obstruction and asthmatic symptoms, the level of baseline eosinophils that predicts a response to treatment, the relationship between blood and airway eosinophilia, and, perhaps most importantly, how to elucidate the pathogenetic role played by eosinophils in the individual patient with severe eosinophilic asthma